www.rttnews.com ·
Macrogenics Secures 122 5m in Manufacturing Sale to Bora Stock Up
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedMacroGenics (biotech) sells its manufacturing facility to Bora Pharmaceuticals (CDMO) for $122.5M, converting a fixed-cost asset into cash while securing supply for its pipeline. The deal reduces MacroGenics' capex and operating costs, improving margin profile, while Bora gains FDA-approved capacity. Impact is company-specific; no broad sector or commodity price effect.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- MacroGenics sells GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million.
- Deal includes Rockville headquarters, FDA-approved facility, Frederick warehouse, and ~140 employees.
- Bora takes over clinical and commercial manufacturing; MacroGenics retains supply arrangement for pipeline.
- Transaction expected to close in Q3 2026.
- MacroGenics stock rose 15.25% in overnight trading to $3.40.
No material sector impact; MacroGenics' margin improvement is isolated to the company. Supply agreement with Bora secures operational stability.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort